TargetMol
CAY10602 is a SIRT1 activator. CAY10602 was derived from high throughput screening for compounds that increase SIRT1-mediated deacetylation of a SIRT1-specific substrate. Functional assays show that CAY10602 dose-dependently suppresses the NF-κB-dependent induction of TNF-α by lipopolysaccharide in THP-1 cells, with approximately 75% inhibition achieved at 60 μM, without cytotoxicity.
More Information
Supplier Page
TargetMol
CAY10602 is a SIRT1 activator. CAY10602 was derived from high throughput screening for compounds that increase SIRT1-mediated deacetylation of a SIRT1-specific substrate. Functional assays show that CAY10602 dose-dependently suppresses the NF-κB-dependent induction of TNF-α by lipopolysaccharide in THP-1 cells, with approximately 75% inhibition achieved at 60 μM, without cytotoxicity.
More Information
Supplier Page
BTB-1
50 mg
| 99.71%
TargetMol
BTB-1
10 mg
| 99.71%
TargetMol
BTB-1
100 mg
| 99.71%
TargetMol
ML329
5 mg
| Purity Not Available
TargetMol
ML329
50 mg
| Purity Not Available
TargetMol
ML329
25 mg
| Purity Not Available
TargetMol
ML329
10 mg
| Purity Not Available
TargetMol
AN2718
10 mg
| 98.89%
TargetMol
AN2718 is a benzoxaborole compound that displays broad antifungal effectiveness in vitro. It inhibits leucyl-tRN/A synthetase (LeuRS) from molds and yeasts (IC50s = 2 and 4.2 μM for A. fumigatus and C. albicans LeuRS, respectively), blocking protein synthesis.
More Information
Supplier Page